Historical Summaries & Sentiment Tracking
cards show the S&P 500's daily move · scroll horizontally → · tracking since Apr 30, 2026
Regime: Risk-On +32
1d · nascent
Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.
Risk-On · supportive
Neutral
Risk-Off · headwind
Stress · fear
Fri
1
7,209
7,229
+0.28%
+1.0
Sat
2
Sun
3
Mon
4
7,230
7,201
-0.40%
-1.1
Tue
5
7,201
7,260
+0.83%
+2.0
Wed
6
7,259
7,366
+1.48%
+2.9
Thu
7
7,365
7,337
-0.38%
-1.1
Fri
8
7,337
7,397
+0.82%
+2.0
Sat
9
Sun
10
Mon
11
7,399
7,413
+0.19%
+0.8
Tue
12
7,413
7,402
-0.15%
-0.6
Wed
13
7,401
7,445
+0.59%
+1.6
Thu
14
7,444
7,502
+0.78%
+1.9
Fri
15
7,501
7,409
-1.23%
-2.3
Sat
16
Sun
17
Mon
18
7,409
7,403
-0.07%
-0.4
Tue
19
7,403
7,355
-0.65%
-1.5
Wed
20
7,354
7,433
+1.08%
+2.3
Thu
21
7,433
7,446
+0.18%
+0.7
Fri
22
7,446
7,474
+0.38%
+1.2
Sat
23
Sun
24
Mon
25
7,446
7,473
+0.37%
+1.2
Tue
26
7,473
7,519
+0.62%
+1.6
Wed
27
7,519
7,521
+0.03%
+0.2
Thu
28
7,520
7,563
+0.57%
+1.6
Fri
29
7,564
7,581
+0.23%
+0.9
Sat
30
Sun
31
Mon
1
7,580
7,600
+0.27%
+0.9
Tue
2
7,600
7,611
+0.14%
+0.6
Wed
3
7,610
7,557
-0.70%
-1.6
Thu
4
7,554
7,585
+0.41%
+1.3
Fri
5
7,580
7,384
-2.59%
-3.7
Sat
6
Sun
7
Mon
8
7,600
7,406
-2.56%
-3.7
Tue
9
7,610
7,387
-2.93%
-4.0
Wed
10
7,554
7,267
-3.80%
-4.7
Thu
11
7,584
7,394
-2.51%
-3.6
Fri
12
7,384
7,431
+0.65%
+1.7
Sat
13
Sun
14
Mon
15
7,406
7,554
+2.01%
+3.5
Tue
16
7,387
7,511
+1.69%
+3.1
Wed
17
7,267
7,420
+2.11%
+3.6
Thu
18
7,394
7,501
+1.44%
+2.8
Fri
19
7,394
7,501
+1.44%
+2.8
Sat
20
Sun
21
Mon
22
7,431
7,473
+0.56%
+1.5
Tue
23
7,554
7,365
-2.50%
-3.6
Wed
24
7,511
7,358
-2.04%
-3.2
Thu
25
7,420
7,357
-0.84%
-1.8
Fri
26
7,501
7,354
-1.95%
-3.1
Sat
27
Sun
28
Mon
29
7,473
7,440
-0.43%
-1.2
Tue
30
7,365
7,499
+1.82%
+3.3
Wed
1
7,358
7,483
+1.70%
+3.2
Thu
2
7,357
7,483
+1.71%
+3.2
Fri
3
7,357
7,483
+1.71%
+3.2
Sat
4
Sun
5
Mon
6
7,354
7,537
+2.49%
+4.1
Tue
7
7,440
7,504
+0.85%
+2.0
Wed
8
7,499
7,483
-0.22%
-0.7
Thu
9
7,483
7,544
+0.81%
+1.9
Fri
10
7,483
7,575
+1.23%
+2.6
Sat
11
Sun
12
Mon
13
7,537
7,515
-0.29%
-0.9
Tue
14
7,504
7,544
+0.53%
+1.5
Wed
15
7,483
7,572
+1.20%
+2.5
Thu
16
7,544
7,534
-0.13%
-0.5
Fri
17
7,575
7,458
-1.55%
-2.6
Sat
18
Sun
19
Mon
20
7,515
7,443
-0.96%
-1.9
Tue
21
7,544
7,509
-0.46%
-1.2
Wed
22
7,572
7,499
-0.97%
-1.9
Thu
23
7,534
7,408
-1.67%
-2.8
Fri
24
7,458
7,412
-0.61%
-1.4
Sat
25
Sun
26
Mon
27
7,443
7,413
-0.40%
-1.1
Tue
28
7,509
7,429
-1.07%
-2.1
Wed
29
7,499
7,316
-2.44%
-3.5
Thu
30
7,408
7,438
+0.40%
+1.2
Fri
31
7,412
7,490
+1.05%
+2.3
Sat
1
Sun
2
Mon
3
7,413
7,601
+2.53%
+4.1
Tue
4
7,429
7,737
+4.14%
+5.6
Wed
5
7,316
7,724
+5.57%
+6.8
Thu
6
7,438
7,710
+3.66%
+5.2
Fri
7
7,490
7,758
+3.58%
+5.1
Sat
8
Sun
9
Mon
10
7,601
7,753
+2.01%
+3.5
Tue
11
7,737
7,728
-0.11%
-0.5
Wed
12
7,724
7,749
+0.32%
+1.1
Thu
13
7,710
7,799
+1.15%
+2.5
Fri
14
7,758
7,786
+0.36%
+1.2
Sat
15
Sun
16
Mon
17
7,753
7,745
-0.10%
-0.5
Tue
18
7,728
7,692
-0.47%
-1.2
Wed
19
7,749
7,708
-0.52%
-1.3
Thu
20
7,799
7,641
-2.02%
-3.1
Fri
21
7,786
7,674
-1.43%
-2.5
Sat
22
Sun
23
Mon
24
Tue
25
Wed
26
Thu
27
Fri
28
Sat
29
Sun
30
Mon
31
Market Recap · July 13, 2026
Flat Day
Divergent High- 50% Markets retreated across all major indices with Russell 2000 down 1.87% and NASDAQ down 0.95%, alongside a VIX uptick of 6.4%, signaling modest risk-off sentiment despite the flat SPY reading; the divergent regime reflects decay at the edges with small caps underperforming large caps.
- 35% Extreme dispersion drove the session narrative with 50 gainers averaging +33% and 50 losers averaging -22%, including transformer moves like VEEE's 416% surge on a merger deal and BNBX's 57% collapse due to Nasdaq delisting; leveraged inverse ETFs (SOXS +14%, QBTZ +14%, IONX -18.6%) and micro-cap biotech plays dominated both lists.
- 15% Financial Services stocks led the gainers with 32% share of the top 50, while Healthcare dominated losers with 27%, signaling a sector rotation away from beaten-down biotech; a 5-name debutant wave surfaced in gainers (ACTU, SEAT, LSTA, EONR, NVNI), hinting at retail exploration of fresh micro-cap territory.
Market Regime
Neutral conf: low macro · prototype+6
VIX17.2
Drawdown-1.3%
Held5d · building
SinceJul 7
Top drivers:
S&P drawdown (60d) ▲
VIX 5d momentum ▼
S&P vs 20d avg ▲
Market Indexes
13
S&P 500
7,515.34
−22.09
-0.29%
Dow Jones
52,498.64
−557.27
-1.05%
NASDAQ Composite
25,873.18
−247.98
-0.95%
NASDAQ 100
29,264.10
−433.77
-1.46%
DJ US Total Market
74,441.29
−396.30
-0.53%
Russell 1000
4,093.01
−20.13
-0.49%
S&P MidCap 400
3,758.76
−58.50
-1.53%
Russell 2000
2,953.17
−56.37
-1.87%
Russell 2500
1,255.05
−9.32
-0.74%
Russell 3000
4,274.13
−23.60
-0.55%
Nasdaq Financial-100
7,429.19
−70.03
-0.93%
NIFTY 50
24,211.00
−187.70
-0.77%
VIX
17.16
+1.03
+6.39%
Biggest Gainers
50Twin Vee PowerCats announced a definitive merger agreement with a subsidiary of USFM Corporation and concurrent privatization of its recreational marine business, triggering a 415% surge as the stock re-rated on the transformative transaction.
The company announced on July 13, 2026 a strategic merger with a USFM Corporation subsidiary alongside a plan to separate and privatize its recreational marine business. The news progression shows the stock jumped 85% on initial announcement, then continued rallying to over 370% intraday and closed near 415% gain. This magnitude of move is consistent with a major M&A catalyst perceived as highly accretive or transformative by the market. The privatization component suggests existing shareholders may receive significant value in the restructuring. Without access to the full merger terms, valuation analysis, or market consensus on deal rationale, we cannot definitively quantify the rational fair value impact, but the scale of the move reflects genuine material corporate news rather than technical or rumor-driven action.
No news headlines were found in the last 48 hours, so the 176.75% jump cannot be attributed to a specific announced event. The move likely reflects either a technical rebound in a micro-cap stock, retail interest, or an undetected news event.
SOBR is a micro-cap stock trading at $1.20, and the absence of any news in the Yahoo Finance RSS feed over the past two days means we cannot identify a fundamental catalyst from public announcements. Stocks in this price range and market cap tier are prone to sharp moves driven by factors other than headline news: short covering, technical bounces after significant declines, retail social media attention, or delayed dissemination of news through alternative channels. The scale of the gain (+176.75%) is substantial enough to suggest either a reversal move on very low trading volume or a catalyst that exists but was not captured in the headline feed provided. Without evidence of earnings, product announcements, clinical results, regulatory approval, or major partnerships, attributing the move to a specific fundamental driver is not possible from the data available.
Q32 Bio stock surged 90.72% after announcing positive Phase 2a trial results showing durable hair regrowth for its alopecia drug bempikibart, combined with a planned stock offering announcement.
The headlines establish a clear two-part catalyst. First, Q32 Bio released positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial on July 13, demonstrating that bempikibart produced hair regrowth that exceeded investor expectations. This was particularly significant given the company had experienced clinical setbacks nearly two years prior that had depressed the stock. The positive data directly addressed investor concerns about the drug's efficacy and de-risked the program. Second, the company announced a proposed public offering of common stock and pre-funded warrants later the same day, which typically indicates management confidence in the pipeline and allows capital raise for ongoing development. The 90.72% gain likely reflects a combination of relief rally on positive clinical validation and momentum from the capital raise announcement signaling near-term runway.
Agenus announced a $340 million private placement financing and a strategic pivot to advance a Phase 3 colon cancer trial (BOT/BAL), triggering an 82.69% single-day surge driven by renewed funding security and clinical focus.
The headlines establish that Agenus announced two coordinated developments on July 13, 2026: an oversubscribed private placement of up to $340 million (with an immediate $85 million tranche and a potential $255 million contingent on future milestones), and a strategic shift to focus financial and clinical resources on a Phase 3 registrational neoadjuvant trial of botensilimab plus balstilimab in high-risk stage 2 and stage 3 colorectal cancer (the ROBBIN trial). The company is simultaneously abandoning its earlier-stage late-line colorectal cancer study. For a pre-revenue or early-stage biotech company, this combination of secured liquidity and sharpened clinical strategy represents a material de-risking event. The oversubscribed placement indicates strong institutional investor confidence. This is a straightforward catalyst-driven move tied to concrete company announcements.
No news headlines were found in the last 48 hours, so the 48.87% gain on FTRK cannot be directly attributed to a specific announcement or event based on available information.
The absence of any recent news headlines makes it impossible to point to a concrete catalyst for the nearly 49% jump in FTRK. For a small-cap or micro-cap stock trading at $0.59, such moves are typically driven by a few common categories: a delayed press release or announcement that has not yet been picked up by major financial news feeds, retail trading momentum or social media amplification, short covering or a squeeze event if the stock has high short interest, technical breakout triggering momentum buying, or a penny stock promotion. Without access to company filings, insider trading reports, or social media discussion around the ticker, we cannot distinguish among these possibilities. The rank as the fifth biggest gainer suggests broad-based movement rather than isolated retail interest, but that remains speculative.
No news headlines were found in the last 48 hours, so the 37.67% gain cannot be directly attributed to a disclosed event. The jump likely reflects technical trading, delayed news pickup, or market speculation in a low-liquidity stock.
The absence of recent news headlines is notable given MIMI's strong single-day performance as the sixth-biggest gainer on NASDAQ. Without disclosed catalysts such as earnings beats, guidance raises, regulatory approvals, or M&A announcements, the move falls into categories typical for smaller-cap stocks: short-covering, retail momentum trading, options-driven gamma effects, or a news event that has not yet been indexed by the financial RSS feeds sampled. Low-float or thinly traded stocks can see outsized percentage moves on modest absolute volume. The timing lag between wire releases and RSS aggregation could also explain why a material announcement exists but did not appear in the 48-hour window queried.
A Form 8.3 disclosure was filed on July 13, 2026, which may relate to material transactions or insider activity, though the headline snippet is truncated and does not fully explain the 35.58% surge in Brera Holdings stock.
The only headline provided is a Form 8.3 filing from July 13, 2026. Form 8.3s typically disclose interests of persons acquiring or dealing with relevant securities in UK-listed companies undergoing takeover offers or schemes of arrangement. The headline text is incomplete—it cuts off after "Ap27"—so the specific content and context of the filing cannot be determined from the information provided. Without knowing whether this relates to a takeover announcement, strategic investment, insider buying, or another material event, it is not possible to confirm that the form filing caused the move. The stock's rank as the seventh-biggest gainer suggests broad market interest, which would typically accompany company-specific news or a catalyst investors recognize. The jump may alternatively reflect a short squeeze, technical rebound, or delayed reaction to an unmentioned development.
No news headlines were found in the last 48 hours for EHGO, so the 29.27% gain cannot be directly attributed to a specific announced event. The move likely stems from technical factors, delayed news dissemination, or market speculation.
The absence of any news headlines in the provided Yahoo Finance RSS feed over the last 48 hours makes it impossible to identify a concrete catalyst for EHGO's sharp 29.27% rally to rank it as the eighth largest gainer on NASDAQ today. This leaves several plausible but unconfirmed explanations. First, the news may exist but simply was not captured in this particular RSS feed, or there may be a delay in headline aggregation. Second, the move could be driven by technical factors such as short covering, options expiration dynamics, or algorithmic trading in a low-liquidity microcap name. Third, an unverified rumor or social media signal may have circulated. Without specific headline evidence pointing to earnings, a partnership, regulatory approval, or other material event, any explanation remains speculative.
No headlines were found in the last 48 hours to explain the 27% gain in ALISR on July 13, 2026, making the cause unclear from public news sources.
ALISR is a rights unit associated with Calisa Acquisition Corp, a blank-check acquisition vehicle. Rights tend to move on news of the sponsor's merger negotiations, deal closure, or redemption/exercise events. Since no headlines appeared in the Yahoo Finance RSS feed for the past two days, the catalyst is not established by public reporting. The move could reflect a delayed market reaction to older news, technical trading in a low-liquidity security, movement in the underlying SPAC common stock, announcement of merger terms or shareholder vote details, or retail interest in a rights offering. Without access to press releases, SEC filings, or SPAC-specific news sources beyond Yahoo Finance RSS, the specific trigger cannot be identified.
No news headlines were found in the last 48 hours, so the 25.47% jump in SKYQ cannot be attributed to a disclosed catalyst. The move likely reflects technical factors, delayed news pickup, or market speculation unconfirmed by available sources.
The absence of recent news headlines makes it impossible to pinpoint a specific catalyst for this significant intraday gain. For a micro-cap stock like Sky Quarry, such moves often stem from several potential sources: technical or momentum-driven trading (particularly if the stock was oversold or part of a sector rotation), delayed reporting of company announcements that haven't yet propagated to major news feeds, short covering or retail trading activity, or undisclosed corporate developments that may be announced after market hours or through channels not indexed by Yahoo Finance RSS. Without access to company filings, press releases directly from the investor relations team, or corroborating news sources, we cannot determine which scenario applies here. The ranking as the tenth biggest gainer suggests broad market awareness, but the absence of headline evidence indicates either the catalyst is not yet public or occurred through non-traditional channels.
No news headlines were found in the last 48 hours, but FIGG is a 2x leveraged long ETF tracking Fiduciary Group (FIG) stock, so a +24.84% gain likely reflects a sharp move in the underlying FIG shares amplified by the 2x daily reset mechanism.
The absence of recent news headlines makes it impossible to identify a specific catalyst for today's movement. However, FIGG's structure as a 2x daily leveraged ETF means it amplifies intraday moves in its underlying FIG holdings. A roughly 12% gain in FIG stock would produce approximately a 24% move in FIGG before accounting for fees and compounding effects, which aligns with the observed price action. The underlying catalyst could be company-specific news, sector rotation, short covering, or technical momentum in FIG shares, but without headlines or access to real-time FIG price data, the root cause remains unconfirmed. Leveraged ETFs are also sensitive to volatility drag and reset mechanics, which can distort the relationship between stated leverage and actual daily returns.
No news headlines were available in the last 48 hours for SRXH, so the 24.55% gain cannot be directly attributed to a reported catalyst. The move likely reflects either a delayed market reaction to older news, technical trading, or an untracked announcement.
The absence of recent news makes it difficult to pinpoint the specific cause of SRXH's strong intraday performance. For a small-cap stock like this trading on AMEX, price moves of this magnitude can result from several sources not always captured in major news feeds: a press release issued outside standard distribution channels, analyst coverage initiation, short-squeeze activity, or options-driven technical moves at key price levels. Alternatively, the move could reflect a delayed market reaction to earnings or corporate news released more than 48 hours ago that is now gaining broader awareness. Without access to the company's investor relations announcements or real-time trading activity, it is not possible to determine whether this was fundamental or technical in nature.
No news headlines were available in the last 48 hours for ACTU, so the 24% gain likely reflects a delayed market reaction to an earlier announcement, technical/short squeeze dynamics, or an untracked catalyst.
Actuate Therapeutics is a small-cap biotech company, and a 24% single-day move on no identifiable news in the immediate window is not uncommon for stocks in this sector. The absence of headlines does not rule out a real catalyst; rather, it suggests either that news broke before the 48-hour window, that market participants are reacting to a filing or press release not yet indexed by major financial news feeds, or that retail/technical trading (including potential short covering) is driving the move. Biotech stocks often experience sharp reversals on clinical trial outcomes, partnership announcements, or regulatory developments. Without access to company filings, SEC documents, or unindexed sources, the true driver remains opaque. The rank as 13 biggest gainer indicates this is a real volume and price event, not a data error.
LogProstyle announced fiscal year 2026 results and a cash dividend of $0.046 per share on July 13, likely driving the 24% gain as investors reacted positively to earnings and the dividend declaration.
On July 13, 2026, LogProstyle released two announcements simultaneously: its fiscal year 2026 financial results and a Board-approved cash dividend of approximately $1.09 million, or $0.046 per share. Both announcements arrived at market open, providing concrete positive catalysts. The dividend announcement alone signals Board confidence in cash generation and returns to shareholders. Without access to the actual earnings figures, revenue trends, or profit margins from the results release, we cannot confirm whether the earnings themselves beat expectations or missed. However, the combination of reported results plus a newly declared dividend typically generates buying interest, particularly in smaller-cap stocks like LGPS trading near $1. The timing and dual announcements on the same day likely amplified retail and institutional interest, consistent with the stock ranking as the 14th biggest gainer on the AMEX that day.
No news headlines were found in the last 48 hours, so the 22.68% jump cannot be attributed to a specific disclosed event; the move likely reflects technical trading, delayed news pickup, or speculation in this micro-cap stock.
AlphaTON Capital Corp. is a micro-cap NASDAQ stock trading at $0.29 with no recent news headlines to explain its significant single-day gain. Stocks in this price range and market-cap category are typically more volatile and prone to outsized percentage moves on thin liquidity, retail trading activity, or rumor. Without disclosed catalysts such as earnings, financing announcements, or operational updates, the most plausible categories of cause include technical bounce-back from oversold conditions, delayed news dissemination to RSS feeds, or speculative positioning. It is also possible that a material announcement was made but has not yet appeared in the headline feed used here, or that the move is driven entirely by intra-day technical factors or social media activity in smaller trading communities that do not immediately surface in major financial news aggregators.
No headlines were found in the last 48 hours, so the 21.97% gain cannot be attributed to reported news; the move likely reflects a technical rebound, short covering, or retail sentiment shift in a micro-cap stock trading at $0.29.
Yahoo Finance returned zero headlines for Alpha Compute Corp in the last two days, making it impossible to tie the jump to a concrete event like earnings, product news, or guidance. A penny stock gaining over 21% intraday without visible news typically reflects one of three mechanics: technical oversold rebound after prior weakness, short-covering as a low-float micro-cap squeezes higher, or retail accumulation driven by social media or scanner activity. Without access to volume trends, short interest data, or chat sentiment, we cannot pinpoint which mechanism applied here. The absence of news does not rule out a delayed or embargoed announcement that may surface later, but that remains speculative.
No news headlines were found in the last 48 hours for TDTH, so the 21.66% jump on July 13 likely reflects a technical rebound, delayed announcement, or retail trading activity rather than a major corporate event.
The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for TDTH's strong single-day gain. Stocks trading at lower price points like $2.64 are often more prone to technical bounces, short covering, or momentum-driven retail interest, especially if the stock had suffered recent declines. It is also possible that a material announcement was made but has not yet been indexed by the Yahoo Finance RSS feed, or that market participants are responding to developments outside major financial press coverage. Without access to company filings, insider activity, or broader sector movements on that date, the most likely explanations are either a technical or sentiment-driven move rather than a fundamental corporate catalyst.
No news headlines were found in the last 48 hours, so the 21% gain on July 13 lacks a clear documented catalyst and may reflect technical trading, delayed announcements, or market rumors.
WFF jumped 21% to rank as the 18th biggest gainer on NASDAQ, yet no news articles appeared in Yahoo Finance's RSS feed during the relevant window. This disconnect between price action and available public information creates uncertainty about the driver. The absence of headlines could mean several things: the catalyst was released outside the monitored news cycle, the move reflects technical factors such as short covering or options expiration activity, market participants may have acted on information not yet widely reported, or the stock could have been subject to speculative buying pressure. Without access to the company's own filings, press releases, or brokerage notes from that specific date, attribution remains speculative. Small-cap stocks like WFF can be more volatile and responsive to lower-volume catalysts that don't always trigger major news coverage.
No news headlines were available in the last 48 hours, so the 20% gain cannot be attributed to a disclosed catalyst; the move likely reflects technical, momentum, or undisclosed catalyst activity.
UBXG jumped 20% on July 13 with zero news coverage in the prior 48 hours according to the provided RSS feed. This disconnect between price action and headline visibility suggests several possibilities: the stock may have experienced technical momentum, short covering, or retail buying interest without corresponding mainstream media coverage. Smaller-cap technology companies sometimes move on sector tailwinds, insider activity, or social media discussion that does not immediately generate financial news headlines. Alternatively, a catalyst may have been announced through other channels (company website, SEC filing, press release not yet indexed) or the move may reflect delayed market reaction to older news. Without access to real-time filings, trading data, or intraday news, attribution remains speculative.
Robo.ai announced that H.E. Ahmed Naser Al-Raisi, former INTERPOL President, has joined as Chairman of its Neurovia AI subsidiary to develop sovereign AI infrastructure in the UAE and GCC region, likely driving the 19.94% gain through positive sentiment around credibility and Middle East expansion.
The headline establishes a specific corporate appointment and strategic expansion announcement. The recruitment of a high-profile former international law enforcement executive as chairman of a subsidiary signals potential credibility enhancement and access to sovereign AI development opportunities in the Gulf Cooperation Council region. This type of announcement—combining geopolitical positioning, governance legitimacy, and emerging-market infrastructure play—typically attracts retail and institutional interest in small-cap tech stocks. The timing of the announcement at market open on 2026-07-13 aligns with the trading day showing the top 20 gainer rank. However, the news snippet is truncated and does not detail financial impact, partnership terms, revenue implications, or funding, so the full strategic scope remains partially unclear.
Battalion Oil Corporation surged 19.62% as oil prices climbed above $80 per barrel following escalating U.S.-Iran military conflict, benefiting the small-cap oil exploration and production company directly through higher crude valuations.
The headline explicitly links BATL's stock movement to a broader oil market rally triggered by geopolitical tension between the U.S. and Iran. As an oil and gas exploration and production company, Battalion's revenue and asset valuations are highly sensitive to crude oil prices. When WTI crude approaches $80 per barrel—up from lower levels—E&P companies with existing production or reserves experience immediate uplift in both current cash flow expectations and the present value of future reserves. The overnight surge on a Sunday session suggests the conflict news broke after regular trading and triggered aggressive buying in oil-correlated equities on Monday open. Small-cap oil stocks like BATL typically amplify moves in the broader oil complex because they have less diversified income and higher leverage to commodity prices. The inclusion of BATL in a headline alongside larger peers (XOM, USO) and crude benchmarks (WTI) confirms the market attributed the move to oil's rise.
No news headlines were found in the last 48 hours. The 19% gain in LAFAR rights is likely driven by technical factors, merger speculation, or retail interest in the underlying SPAC, but the specific catalyst cannot be identified from available information.
LAFAR is a SPAC rights offering, a security type that tends to be illiquid and volatile even on low-volume moves. The absence of any news headlines in the Yahoo Finance RSS feed in the past 48 hours means the jump cannot be attributed to a disclosed corporate event, earnings report, or regulatory action. For a blank-check company rights offering, typical catalysts include renewed speculation about a pending merger deal, technical rebalancing by algorithmic traders, short covering, or increased retail or institutional interest in the parent SPAC. Rights on SPACs can also experience outsized percentage moves on relatively small dollar volumes due to their illiquid nature. Without a specific headline or filing to anchor the explanation, the move remains speculative and difficult to attribute to a single cause.
No news headlines were found in the last 48 hours, but IONZ is a 2x inverse leveraged ETF tracking IONQ, so a sharp decline in IONQ stock would directly drive an 18.59% gain in this short ETF.
The absence of recent news about IONZ itself is expected, as this is a specialized inverse leveraged ETF rather than an operating company. IONZ is structured to amplify short exposure to IonQ by 2x daily, meaning a roughly 9% drop in IONQ stock would produce approximately the observed 18.59% gain in IONZ. The most likely catalyst is therefore a significant decline in IonQ's share price over the snapshot period. Without access to IONQ's price action on 2026-07-13 or any earnings, product, or competitive announcements affecting IonQ, the exact trigger for that underlying move cannot be determined from the information provided. This could reflect earnings disappointment, guidance revision, sector headwinds, or other fundamental or technical factors affecting quantum computing stocks.
No news headlines were found in the last 48 hours for TMDE, so the 18% gain cannot be attributed to a specific announced event; the move likely reflects either technical trading, delayed news dissemination, or market speculation.
The absence of any recent news headlines for TMDE makes it impossible to identify a concrete catalyst for the 18% single-day jump. This is a microcap stock trading on AMEX at under $1, which typically means limited analyst coverage and news flow. Possible explanations include: first, a technical rebound or short squeeze if the stock had been heavily shorted or oversold; second, a delayed market reaction to news that may not yet be reflected in the RSS feed provided; or third, market-wide momentum or sector rotation affecting small-cap energy names. Without additional information about TMDE's business, recent fundamentals, or trading structure, we cannot distinguish between these scenarios. The timing and magnitude suggest something beyond random noise, but the evidence simply does not support a specific identification.
No news headlines were found in the last 48 hours for BRR, so the 17.81% gain likely reflects a technical bounce, delayed market reaction to an older announcement, or an untracked catalyst such as an earnings report or press release not yet indexed by Yahoo Finance.
The absence of recent news headlines in the Yahoo Finance RSS feed makes it difficult to pinpoint a specific catalyst for the 17.81% intraday gain. ProCap Financial (BRR) is a micro-cap stock trading at $1.72, and such stocks are often subject to liquidity-driven moves, short-covering, or delayed dissemination of company announcements. Possible explanations include a quarterly earnings report released before the RSS snapshot, an investor presentation, insider buying, or simple technical mean reversion if the stock had been oversold. Without access to the company's investor relations website or real-time news wires, it is impossible to confirm whether a material event occurred on or just before July 13, 2026. The lack of indexed coverage does not rule out a legitimate announcement; it only indicates the evidence is not currently available.
No news headlines were available in the last 48 hours, so the 17% jump in VIVK cannot be directly attributed to a published catalyst. The move likely reflects technical trading, delayed news pickup, or market rumors.
Vivakor is a micro-cap stock trading at $0.31, and no headlines appeared in the Yahoo Finance RSS feed within the snapshot window. Without published news, the gain is unexplained by major corporate events such as earnings, contract awards, financing announcements, or regulatory actions. For stocks in this price range and market cap category, moves of this magnitude are often driven by factors other than fundamental news: short-covering, options expiration effects, social media or message board activity, delayed news dissemination, or speculative positioning by retail traders. It is also possible that relevant news exists but was not indexed by the news feed used for this analysis. Without specific evidence, attributing the move to any particular catalyst would be speculation.
No news headlines were found in the last 48 hours, so the 16.67% gain likely stems from technical factors, delayed news pickup, or market sentiment shift rather than a named catalyst.
Interactive Strength Inc. jumped 16.67% with no corresponding news coverage in the Yahoo Finance RSS feed over the past two days. This disconnect suggests either the catalyst is recent and not yet widely reported, or the move is driven by technical factors such as short covering, options activity, or general retail interest in the microcap space. Without access to earnings releases, company announcements, FDA actions, or partnership news, we cannot pinpoint a specific fundamental driver. For a stock trading at $3.01, momentum-driven moves and low float dynamics are common, and a lack of news coverage does not rule out material events that simply have not yet propagated through major news feeds.
Braiin launched ARIA, a new agentic AI platform targeting the $32 billion global real estate software market, prompting a 16.6% gain as investors responded positively to the product expansion and market opportunity.
Multiple sources on July 13 confirm Braiin announced ARIA, described as an AI-native agentic platform designed to automate multi-step real estate workflows across property management, leasing, compliance, accounting, and customer engagement. One headline notes the stock surged 34% following the release, though the snapshot shows a 16.59% gain, suggesting either intraday volatility or the snapshot timing relative to peak momentum. The announcement directly addresses a stated growth vector for the company—expansion into the real estate software sector—and positions it within the broader agentic AI trend that has driven investor interest in AI stocks. The $32 billion market sizing provides a clear narrative of addressable opportunity. No earnings, guidance revision, or partnership detail is visible in the headlines, so the move appears driven by product launch enthusiasm and sector positioning rather than financial performance.
No news headlines were found in the last 48 hours, so the 16.29% gain on BVC cannot be attributed to any identified recent announcement or event disclosed in major financial media.
BitVentures Limited jumped 16.29% on July 13, 2026, but no news appeared in the Yahoo Finance RSS feed during the prior 48 hours to explain the move. This creates a gap between price action and public disclosure. Possible drivers for a cryptocurrency or blockchain-focused microcap like BVC might include a delayed press release not yet indexed by major wires, social media momentum or retail interest in the crypto or fintech space, technical rebound from an oversold level, insider activity ahead of an unannounced catalyst, or general sector rotation. Without access to the company's direct announcements, SEC filings, or social media discussions, these remain hypothetical categories rather than evidence-based explanations.
No news headlines were found in the last 48 hours, so the 16.22% gain on AURE likely stems from technical trading, short covering, or undisclosed company developments not yet reported by major news outlets.
The absence of any news in the Yahoo Finance RSS feed over the past 48 hours means we cannot point to a specific catalyst such as earnings, FDA approval, partnership announcement, or guidance change. A 16% single-day move on a stock trading near $1.72 suggests either significant technical momentum, possible short squeeze activity if the stock has elevated short interest, retail trading interest in a low-priced name, or an announcement that has not yet been indexed by the RSS feed. Penny and micro-cap stocks like this are also more prone to intraday volatility and gap moves driven by thin liquidity or after-hours developments. Without corroborating news or access to company filings, we cannot isolate the specific driver.
No specific news catalyst was found in the provided headlines. The 16.19% jump in KOS today likely reflects either sector rotation within energy stocks, technical momentum, or an unreported company-specific development.
The only headline provided is a generic sector comparison article mentioning both Calumet (CLMT) and Kosmos Energy (KOS) without disclosing any material news about either company. No earnings release, dividend announcement, operational update, contract win, or guidance change is documented in the available news feed. For an oil and gas exploration and production company like Kosmos, typical catalysts driving large single-day moves include reserve discoveries, production updates, debt restructuring announcements, or broader energy price movements. The absence of identified news combined with a top-31 ranking among daily gainers suggests either a delayed announcement has not yet been indexed by the news feed, market-wide energy sector momentum is driving KOS higher alongside peers, or the move is driven by technical factors or trading activity not reflected in public headlines.
No news headlines were found in the last 48 hours, so the 16% gain on DTSQR is unexplained by reported developments; the move may reflect technical trading, delayed news disclosure, or speculative activity typical of blank-check acquisition vehicles.
DT Cloud Star Acquisition Corporation is a SPAC, a shell company created to acquire a private business and take it public. No headlines in the past 48 hours explain today's 16% rally from $0.13 to $0.15. SPACs are sensitive to several categories of catalyst: announcement of a merger target, termination of a failed deal hunt, changes in warrant or unit redemption terms, news about the eventual business combination partner, or simply technical/sentiment shifts in a thinly traded security. Given the complete absence of news, the move likely reflects either an undisclosed announcement not yet indexed in financial news feeds, speculative accumulation ahead of known milestones (redemption dates, shareholder votes, etc.), or routine volatility in a low-price micro-cap. Without reported news, the cause remains inference-level guesswork.
No news headlines were published about SEAT in the last 48 hours, so the 14.90% gain likely stems from technical trading, market sentiment shift, or an unannounced catalyst that has not yet surfaced in major financial media.
Vivid Seats is a secondary ticketing marketplace, and stocks in this category can be sensitive to broad consumer discretionary sentiment, event calendar strength, or short-covering activity. Without any news anchoring the move, the jump could reflect several types of catalysts: a positive shift in near-term event demand or touring schedules, technical oversold recovery, positive commentary on social media or trading forums, or short-squeeze mechanics if the stock carries a meaningful short interest. It is also possible that news exists but has not yet been picked up by the Yahoo Finance RSS feed in the 48-hour window provided. Earnings, guidance, partnership announcements, or insider activity are all plausible underlying drivers, but none can be confirmed from the evidence at hand.
No news headlines were found in the last 48 hours, so the 14.85% gain likely reflects either a technical rebound in a low-priced SPAC, short covering, or a delayed market reaction to an earlier event not captured in the data provided.
ChampionsGate Acquisition Corporation is a blank-check acquisition company trading at $0.15, making it highly sensitive to small-volume trades and technical movements. The absence of any news in the last 48 hours means the jump cannot be attributed to a specific catalyst such as a merger announcement, earnings report, or business update. For a SPAC trading near or below its $0.01 nominal value, moves of this magnitude can be driven by several factors: short covering or a squeeze in thinly traded securities, a delayed market reaction to older news not captured in this 48-hour window, speculative retail interest, or simple technical mean reversion. Without additional context on the float, short interest, or trading volume, we cannot pinpoint which mechanism is at work here.
No news headlines were published in the last 48 hours for CAST, so the 14.69% gain on July 13 cannot be attributed to a specific disclosed catalyst. The move likely reflects technical trading, retail interest, or undisclosed market activity.
FreeCast is a small-cap stock trading at $3.28 with no recent news coverage in the Yahoo Finance RSS feed covering the last two days. Without headline-driven catalysts such as earnings announcements, partnership agreements, or guidance changes, the sharp 14.69% intraday gain suggests other forces at work. For stocks of this size and market position, typical drivers of unexplained moves include short-squeeze activity (particularly if short interest is elevated), retail trading enthusiasm, options-related activity, or technical breakouts above resistance levels. It is also possible that a material announcement was made through non-traditional channels or that the move reflects catch-up trading following earlier market developments not yet reflected in major news feeds. Without additional context, pinpointing the specific catalyst is not possible from the available evidence.
No news headlines were found in the last 48 hours, so the 14.56% jump on July 13 likely stems from technical factors, delayed market reactions to earlier announcements, or untracked catalysts specific to Nuvve's vehicle-to-grid technology sector.
Nuvve Holding Corp. experienced a significant single-day gain of 14.56%, ranking among the day's top 36 gainers, yet no relevant news appeared in the RSS feed covering the prior 48 hours. This disconnect suggests the move was either driven by older news (beyond the 48-hour window), technical or momentum-based buying in a micro-cap EV or energy-storage play, or an announcement not yet indexed by Yahoo Finance. Nuvve operates in the vehicle-to-grid (V2G) charging space, which is capital-intensive and sensitive to contract wins, regulatory tailwinds, and sentiment shifts around EV adoption. Without confirmed headlines, plausible mechanisms include a delayed earnings release, industry-level positive sentiment, short covering, or an unconfirmed rumor circulating among retail traders.
No news was available in the last 48 hours; the 14.18% gain likely reflects a sharp rise in crude oil prices or broader energy sector strength, which a 3x leveraged oil ETN would amplify significantly.
No headlines appeared in the Yahoo Finance RSS feed for the past 48 hours, so we cannot attribute this move to a specific corporate announcement, earnings release, or policy change. However, NRGU is a 3x leveraged inverse or bullish bet on U.S. large-cap energy companies, making it highly sensitive to commodity price movements. A 14.18% single-day jump in a leveraged ETN typically reflects either a substantial move in the underlying oil index or energy sector equities, or volatility-driven rebalancing effects in leveraged products. Oil prices, geopolitical events, OPEC announcements, or broad market risk-on sentiment could all drive such a move, but without news coverage provided, the specific catalyst remains unidentified.
No news headlines were found in the last 48 hours, but QBTZ is a 2X inverse leveraged ETF tracking the Nasdaq-100, so a sharp 14% gain likely reflects a significant decline in its underlying index or QBTS basket.
QBTZ is a daily inverse leveraged ETF designed to move roughly negative 2X the daily performance of its benchmark. With no news headlines available, the 14% gain almost certainly stems from a substantial drop in the Nasdaq-100 or the QBTS index itself rather than from company-specific or sector-specific news. Inverse leveraged ETFs amplify downside moves in their underlying, so if the Nasdaq declined roughly 7% or more on July 12–13, QBTZ would naturally gain 14% or more as a mechanical result. This type of move is typical for inverse ETFs during broad market selloffs, technical corrections, or volatility spikes. Without market data or news explaining the underlying decline, the cause remains unidentified but the mechanism is structural.
No news headlines were found in the last 48 hours, but SOXS is a 3X inverse leveraged ETF that gains when semiconductor stocks fall sharply, so a major selloff in the chip sector on 2026-07-13 likely triggered this 14% jump.
The absence of any news in the provided headline feed makes it impossible to pinpoint a specific catalyst. However, SOXS is a Direxion Daily Semiconductor Bear 3X ETF, meaning it is designed to deliver triple the inverse daily performance of semiconductor equities. A 13.97% gain in this security strongly implies a significant decline in the underlying semiconductor index on that date. Such a move could stem from several categories of events typical for this sector: broad market risk-off selling, semiconductor-specific headwinds such as demand concerns, supply chain disruption, regulatory action, geopolitical tension affecting chip supply, or disappointing forward guidance from major players. Without explicit news, the cause remains structurally inferred rather than confirmed by reporting.
No news headlines were available in the last 48 hours, so the 13.95% gain cannot be attributed to a specific disclosed event; the move likely reflects technical trading, delayed news dissemination, or undisclosed company developments.
GIBO Holdings experienced a significant one-day gain of nearly 14% with no corresponding headlines in the Yahoo Finance RSS feed over the preceding 48 hours. This disconnect between price action and available public news creates genuine uncertainty about the catalyst. Without knowing GIBO's sector, market cap, trading volume, or historical volatility profile, several plausible explanations emerge. Stocks in growth or speculative categories sometimes experience sharp rallies on thin or delayed news coverage, sector rotation flows, or technical breakouts that precede formal announcements. Alternatively, the news may have been published through non-RSS channels or the timing gap between the move and indexing of headlines may be significant. A smaller-cap stock might also rally on insider activity, analyst upgrades, or positive commentary that spreads through research networks before hitting mainstream feeds.
No news headlines were available in the last 48 hours, but RGTZ is a 2X leveraged inverse ETF, so a sharp gain reflects a sharp decline in its underlying index, most likely driven by broad market weakness or sector-specific selloff.
No headlines from the last 48 hours were provided to explain the move directly. However, RGTZ is a Daily Target 2X Short ETF, which means it is designed to move roughly twice as much as its underlying index in the opposite direction. A 13.72% gain in RGTZ therefore implies the underlying asset fell roughly 6 to 7 percent on the day (accounting for leverage and daily rebalancing effects). This type of move is typically explained by significant equity market declines, broad risk-off sentiment, or a sharp drop in the specific sector or index the ETF tracks. Without headline confirmation, the cause could be macroeconomic data releases, Federal Reserve signals, geopolitical events, or earnings disappointments affecting the benchmark. The absence of news does not rule out a major market event; it simply means corroborating detail is unavailable here.
No news headlines were found in the last 48 hours, so the cause of Galectin's 13.3% jump cannot be directly attributed to a named event. The move likely reflects either delayed reaction to prior news, sector momentum, or speculative trading in this small-cap biotech stock.
Galectin Therapeutics is a clinical-stage biopharmaceutical company focused on galectin inhibitors for liver fibrosis and cancer. With no headlines in the recent 48-hour window, the jump cannot be tied to earnings, FDA decisions, trial results, or partnership announcements that would normally drive a move of this magnitude in a development-stage biotech. For stocks in this category, typical catalysts include positive clinical trial data releases, regulatory feedback, funding announcements, or management changes. Alternatively, the move could reflect technical factors such as short covering, a broader biotech sector rally, or retail investor activity that precedes formal news dissemination. Without access to after-hours trading data, SEC filings, or company press releases outside the Yahoo Finance RSS feed, the specific trigger remains unclear.
No news was reported in the last 48 hours, so the 13.15% jump likely reflects either a delayed market reaction to an earlier announcement, technical trading activity, or an undisclosed development in this small-cap biotech stock.
The absence of recent headlines in the Yahoo Finance RSS feed makes it difficult to pin down a specific catalyst for the move. Lisata Therapeutics is a small-cap biopharmaceutical company, and stocks in this category are often sensitive to clinical trial updates, regulatory filings, partnership announcements, or strategic pivots that may not immediately appear in broad financial news feeds. The move could also reflect short covering, options-related buying, or technical momentum in a thinly traded security. Without corroborating news, the timing of the jump and its magnitude suggest either delayed dissemination of company news, insider-informed trading ahead of an announcement, or momentum-driven activity typical of micro-cap biotech stocks. A direct check of the company's investor relations page or SEC filings would be necessary to identify the actual driver.
No news headlines were found in the last 48 hours for APURR, so the cause of the 13.05% gain cannot be identified from available reporting. The move likely stems from technical trading, a delayed announcement, or retail interest.
The absence of any news in the Yahoo Finance RSS feed over the past two days makes it impossible to attribute the stock's 13.05% jump to a specific corporate event. APURR trades at $0.19, which places it in the micro-cap category where price moves are often driven by factors other than traditional news catalysts. Possible explanations include short covering in a thinly traded stock, retail trading activity or social media discussion, technical chart breakouts, sector rotation into small-cap equities, or delayed disclosure of information not yet indexed by major news aggregators. Without headline evidence or structural knowledge of the company, any explanation remains speculative.
No news headlines were available in the last 48 hours for SOC, so the 13% gain cannot be attributed to a publicly reported event. The move likely stems from technical factors, delayed news dissemination, or market speculation.
Sable Offshore Corp. experienced a 13.01% jump on July 13, 2026, ranking it the 45th biggest gainer for the day, but no news headlines from the past 48 hours are available to explain the move. This absence of reportable news is itself notable for a stock with that magnitude of daily movement. Possible catalysts in the inference category include technical momentum or short covering, particularly if SOC trades with low liquidity or has significant short interest. Alternatively, the stock may have responded to sector-wide developments in offshore energy or oil markets that were not captured in the headline feed provided, or there may be a delay in news publication to Yahoo Finance RSS. Without concrete information, the cause remains speculative.
No headlines were published in the last 48 hours covering MYSE, so the 12.99% jump cannot be directly attributed to announced news. The move likely reflects technical factors, delayed news pickup, or market rumors.
Yahoo Finance's RSS feed returned zero headlines for MYSE in the 48-hour window preceding this +12.99% gain on July 13, 2026. This absence of coverage does not rule out a catalyst but means we cannot identify what it was from the provided evidence. For a micro-cap stock like MYSE trading at $2.61, typical catalysts driving single-day rallies of this magnitude include earnings surprises or guidance beats that may not yet have full media coverage, short-squeeze activity or unusual options flow, analyst upgrades or rating changes, or regulatory or corporate announcements that bypass traditional news feeds initially. Without access to earnings calendars, SEC filings, or real-time data, we cannot determine which of these categories applies here.
No news headlines were found in the last 48 hours to explain the 12.96% gain in HCICR. The move likely reflects technical trading activity, options positioning, or routine volatility in a low-priced rights offering security.
HCICR is a share rights offering from Hennessy Capital Investment Corp. VIII, a blank-check company vehicle. No substantive news was published in the last 48 hours, so the gain cannot be attributed to a named catalyst, earnings announcement, merger development, or regulatory action. Rights offerings and low-priced SPAC-related securities are prone to tactical trading, retail activity, and options-driven moves that can cause outsized percentage swings on modest dollar volume. The 12.96% move on a $0.19 security is notable in percentage terms but represents minimal absolute price movement and may reflect technical support, short covering, or algorithmic rebalancing rather than new fundamental information. Without headlines, the true driver remains opaque.
No news headlines were found in the last 48 hours, so the 12.85% gain in ARAY stock cannot be attributed to a disclosed catalyst. The move may reflect technical buying, short covering, or undisclosed developments.
The absence of any recent news headlines makes it impossible to pinpoint a specific catalyst for Accuray's strong single-day gain. ARAY is a medical device company focused on radiation oncology and radiosurgery systems, which typically trades on clinical/commercial developments, regulatory approvals, contract wins, or quarterly results. Given the magnitude of the move and the lack of public disclosure, potential explanations include short covering by algorithmic traders, a delayed market reaction to older news not captured in the 48-hour window, technical chart breakout triggering momentum buying, or undisclosed material information that has not yet been widely reported. Without access to insider trading reports, conference call activity, or direct company communication, the true driver remains speculative.
No headlines were published in the last 48 hours explaining EONR's +12.80% jump. The move was likely driven by technical factors, delayed news pickup, or market rumors involving this micro-cap stock.
Yahoo Finance returned zero news headlines for EONR in the 48-hour window prior to this snapshot, so there is no news-based explanation available for the price action. EONR is a micro-cap trading on AMEX at $0.56, a category of security that often experiences large percentage swings on modest volume and can be sensitive to retail interest, technical chart breakouts, or rumor-driven trading that precedes formal news distribution. The stock ranked as the 49th biggest gainer of the day, suggesting broad intraday momentum, but without corroborating headlines, headlines, or company filings visible in this dataset, the specific catalyst remains unknown. Possibilities include an off-the-wire earnings release, a merger rumor, insider buying, or simply a technical rebound after prior weakness, but none can be confirmed from the evidence provided.
No news headlines were available in the last 48 hours for NVNI, so the 12.73% gain likely reflects technical trading activity, delayed news release, or market rumors rather than a confirmed corporate announcement.
The absence of any news in the Yahoo Finance RSS feed over the past 48 hours makes it difficult to pinpoint a specific catalyst for the stock's sharp 12.73% intraday gain. NVNI is a micro-cap equity trading at $1.24, a price point where stocks are often subject to higher volatility and retail trading activity. Possible drivers of such a move in the absence of headline news include technical chart reversals after oversold conditions, accumulation by short-squeeze participants, delayed or yet-to-be-widely-reported company announcements not yet indexed by major news aggregators, or market-wide sector rotation. Without corroborating headlines or structural knowledge of the company's recent circumstances, only generic categories of causation can be identified.
Biggest Losers
50BNB Plus Corp. received a Nasdaq delisting determination on 2026-07-13 due to failure to meet the exchange's minimum bid price requirement and will move to the OTCQB market, triggering a 56.75% single-day collapse as investors flee the security ahead of the transition.
The headline directly establishes that Nasdaq has made a delisting determination against BNB Plus, citing the minimum bid price rule violation. The company plans to request a Nasdaq review, but the delisting notice itself is the triggering event. A move from Nasdaq to OTCQB typically involves severe liquidity deterioration, wider bid-ask spreads, reduced institutional access, and lower analyst coverage, all of which justify a sharp equity repricing downward. At $0.16, the stock appears already near penny-stock territory, meaning the delisting determination formalizes what the market had likely been pricing in partially. The magnitude of the decline reflects both the formal delisting announcement and the structural impairment to the security's investability that follows.
No news headlines were found in the last 48 hours, so the 41.6% single-day drop likely reflects either a delayed earnings release, contract loss announcement, or other material event that has not yet appeared in tracked news feeds.
The absence of any recent headlines despite a massive one-day decline is the defining feature here. DWSN is a seismic data acquisition services company operating in the energy and resource exploration sector, which makes it vulnerable to commodity price swings, oil and gas spending cycles, and major contract wins or losses. A drop of this magnitude on a stock of this size typically signals a material negative event—most commonly a missed or poor earnings report, loss of a major client or contract, downward guidance revision, or operational disruption. The timing gap between the price action and available news could mean the announcement occurred after typical market close reporting, is still propagating through news aggregators, or that management has disclosed material information via SEC filing or conference call that has not yet reached Yahoo's RSS feed. Oil and gas exploration spending cuts by majors, or a surprise quarterly loss, would fit this pattern.
Matinas announced a transformational business combination with GH Power to pivot into clean energy and green hydrogen, while simultaneously divesting its core LNC pharma platform to Azurity, signaling a complete strategic exit from its original biopharma business and triggering investor concern o…
The two simultaneous announcements represent a radical strategic pivot. Matinas is abandoning its legacy pharmaceutical pipeline, including lead candidate MAT2203, by selling it to Azurity while merging with GH Power, a private clean energy company focused on green hydrogen and critical materials. This combination is structurally similar to a reverse merger or SPAC transaction, where private company shareholders will receive equity in the public shell, typically causing dilution to existing shareholders. Investors in a biopharma company trading at $0.48 are now being asked to accept conversion into a clean energy venture, introducing execution risk, sector change, and dilution without visibility into valuation terms, GH Power's financials, or the deal's timeline to completion. The sale of the pharma assets also eliminates the company's core pipeline, leaving only an unproven clean energy business. This combination of dilution, strategic abandonment of original assets, and sector pivot likely triggered heavy selling among existing shareholders unwilling to roll into a speculative green hydrogen play.
Factorial Energy fell 35.62% on the same day it announced a strategic partnership with Tulip Seal and a successful flight test showing 30% increased range, suggesting the market either viewed the news as priced-in, disappointing relative to expectations, or reacted to an unrelated catalyst.
The headline from 2026-07-13 announces a positive development: a strategic partnership between Factorial and Tulip Seal following a successful flight validation that achieved more than 30% improvement in flight range. Ordinarily, such a partnership and performance milestone would be viewed favorably. However, the timing of the 35.62% intraday collapse on the same day the news broke raises several possibilities. The market may have already priced in expectations of this partnership or a stronger result, making the announced achievement underwhelming by comparison. Alternatively, the headline itself may be incomplete or lack detail on commercialization timelines, revenue projections, or exclusivity terms that investors needed to justify current valuation. A third possibility, though unsupported by provided evidence, is that a separate negative catalyst unrelated to this partnership announcement drove the decline—such as a simultaneous earnings miss, guidance cut, financing announcement, or sector headwind in battery or drone technology stocks.
No headlines were found in the last 48 hours, so the cause of the 33% drop cannot be determined from news. The decline likely stems from company-specific fundamentals, clinical trial results, or market sentiment shifts typical of small-cap biotech stocks.
AEON Biopharma is a small-cap biotech company trading at $0.32, and the absence of any news coverage in the prior 48 hours makes direct attribution impossible. However, micro-cap biotech stocks commonly experience sharp selloffs due to several categories of catalyst: adverse clinical trial data or delays, cash burn concerns and financing questions, leadership changes, or shifts in market sentiment toward the sector. Without headlines to reference, we cannot determine which specific event triggered today's 33% decline. It is also possible the move reflects accumulated negative sentiment from an earlier announcement that did not generate fresh Yahoo Finance headlines in the most recent 48-hour window, or reflects technical selling in an illiquid stock with thin trading.
No news headlines were found in the last 48 hours explaining ZBAO's 31.69% drop on July 13, 2026, making it impossible to attribute the move to a specific catalyst from available public information.
The absence of recent headlines is notable given the severity of the move, ranking ZBAO as the sixth-biggest loser of the day. For a micro-cap stock trading at $0.29, large single-day declines can result from several sources: delayed announcements picked up only on specialized financial feeds not captured in this RSS feed, a broader sector selloff, technical break of support levels triggering stop-loss orders, or ordinary market liquidity constraints in a thinly traded security where small volume shifts create large percentage moves. Penny and near-penny stocks are particularly susceptible to volatility from rumors or trading algorithm behavior that may not generate formal news coverage. Without confirming headlines or structural context about the company, only generic speculation is possible.
No news headlines were found in the last 48 hours, so the 30.41% drop cannot be directly attributed to a reported event. The decline likely reflects technical selling, a delayed market reaction to earlier news, or sector-specific pressure affecting this micro-cap stock.
The absence of any news in the provided RSS feeds over the last 48 hours makes it impossible to pin the drop to a specific catalyst such as earnings, guidance, regulatory action, or corporate announcement. JZXN is a micro-cap NASDAQ-listed company, and stocks in this category are typically more volatile and susceptible to technical factors, short covering reversals, or shifts in broader market sentiment toward the sector. A 30.41% single-day loss of this magnitude in a thinly traded name could reflect liquidation, a delayed market digestion of older news not captured in the 48-hour window, or simply a loss of momentum in speculative holdings. Without headline support, we cannot determine whether the move is news-driven or technical.
No news headlines were found in the last 48 hours, so the 30% drop cannot be attributed to a disclosed catalyst. The decline may reflect technical selling, market sentiment, or an unannounced development not yet reported.
The absence of any news in Yahoo Finance's RSS feed over the last 48 hours means we cannot point to a specific earnings miss, product announcement, regulatory action, or guidance revision as the cause. YSXT experienced a severe single-day decline ranking it the 8th biggest loser on NASDAQ, which typically requires either a material negative catalyst or significant technical breakdown. For a micro-cap stock trading at $0.70, liquidity constraints and momentum-driven selling can amplify intraday moves sharply. Possible explanations include delayed disclosure of bad news, a liquidity event, short covering reversals, or sector-wide pressure in technology stocks on that date, but without corroborating headlines this remains speculative.
No news headlines were found in the last 48 hours, so the 29.33% decline cannot be directly attributed to a specific announced event; the drop likely reflects broader market sentiment, technical selling, or undisclosed company developments.
The absence of recent headlines makes it difficult to pinpoint a concrete catalyst for JLHL's sharp 29.33% decline. Without earnings reports, guidance changes, regulatory actions, or material announcements documented in the available news feed, the move appears to stem from either technical factors such as momentum selling or stop-loss triggers, broader sector weakness affecting China-based or small-cap NASDAQ stocks, or potentially an unannounced development not yet reflected in major news outlets. Stocks trading at lower price points and with smaller market caps can experience outsized intraday volatility driven by liquidity constraints or algorithmic trading. It is also possible that news was disseminated through channels not captured by the Yahoo Finance RSS feed provided.
No news headlines were found in the last 48 hours, so the 27.75% drop cannot be directly attributed to a disclosed event. The decline likely reflects either a delayed market reaction to prior news, a clinical or regulatory setback specific to BioVie's pipeline, or broad sector pressure on small-c…
BioVie is a small-cap biopharmaceutical company with a market cap under $100 million based on the stock price, making it highly volatile and sensitive to clinical trial updates, FDA decisions, or cash runway concerns. The absence of headlines in the last 48 hours suggests either that a significant negative event has not yet been widely reported by financial media, or that the market is reacting to an older announcement that has only now gained traction or been reassessed by investors. For micro-cap biotech firms, major catalysts include Phase trial results, Investigational New Drug application status, licensing deals, or funding announcements. Given the magnitude of the drop, the most likely explanations are a clinical trial setback, regulatory rejection, or adverse data release that occurred within the past week but was not immediately captured in this news feed, or a substantial capital raise at a depressed valuation that dilutes existing shareholders.
Haoxi Health completed a $4 million registered direct offering on July 13, which typically causes immediate shareholder dilution and downward price pressure, explaining the 26% single-day decline.
The headline confirms that Univest Securities closed a $4 million registered direct offering (RDO) for Haoxi Health on the same day as the stock's 26% drop. RDOs are a form of equity financing that involve the issuance of new shares at a negotiated price, usually below current market value or at a discount. This creates two mechanical headwinds: first, existing shareholders are diluted by the new share count; second, the terms of RDOs often signal that management needed capital urgently and at unfavorable terms, which markets interpret as weakness. The timing matches perfectly—the news broke after market close on July 13, the same date of the decline. No other material news is present in the provided headlines, so the offering appears to be the primary catalyst for the sell-off.
Banzai International announced a $0.9 million underwritten public offering on July 13, which likely triggered the 25.93% stock decline due to shareholder dilution concerns and the signal that the company is raising capital at depressed valuation levels.
The headline confirms that Banzai announced an underwritten public offering of $0.9 million on the same day as the sharp sell-off. Public offerings typically pressure stock prices through two mechanisms: immediate dilution of existing shareholder ownership and, more broadly, the market signal that management is raising capital, which often reflects either operational need or a judgment that the stock is fairly or overvalued at current levels. The relatively modest size of the raise ($0.9 million) and the timing of the announcement during trading hours on the day of the drop establish a clear temporal and causal link. No offsetting positive information about use of proceeds or strategic rationale is provided in the headline snippet, leaving investors focused on the dilution aspect. This represents a textbook equity offering sell-off.
No news headlines were found in the last 48 hours, so the 25.62% drop cannot be tied to a specific announced event; the cause likely stems from technical selling, sector rotation, a delayed earnings miss, or other market-driven factors.
ZCMD experienced a severe single-day decline of over 25% with zero news coverage in the prior 48 hours according to the data provided. This disconnect between magnitude of move and absence of headline-driven catalysts suggests the sell-off may be driven by technical factors such as stop-loss cascades, margin calls, or sector-wide pressure on small-cap stocks. Alternatively, the decline could reflect a delayed market reaction to news released outside the 48-hour window, an unannounced earnings shortfall, insider activity, or short-seller activity that has not yet been publicly reported. Without access to real-time trading data, volume patterns, or additional company filings, it is not possible to isolate the precise trigger. ZCMD trades at a low absolute price point, which can amplify intraday volatility and may attract retail or algorithmic trading flows.
No news headlines were found in the last 48 hours to explain the 25.22% drop. Since APPX is a 2X leveraged ETF tracking APP, the decline likely reflects a sharp fall in the underlying APP stock amplified by the fund's leverage structure.
The absence of any recent news in the search results means we cannot point to a specific corporate event such as earnings, guidance, regulatory action, or M&A activity. However, APPX is a 2X leveraged daily ETF designed to deliver twice the daily return of its underlying index or stock. This means that if the underlying APP stock fell roughly 12-13% in a single day, the leveraged fund would amplify that move to approximately 25%. The sharp one-day loss is therefore most consistent with a significant decline in APP itself rather than a fund-specific issue. Without visibility into what drove APP lower, we cannot identify the root catalyst, but the magnitude of APPX's move is structurally explained by its leverage multiplier rather than any unique event in APPX itself.
Apollomics announced regained Nasdaq compliance on July 13, but this positive development coincided with a steep 25% single-day drop, suggesting the market may have reacted negatively to hidden news in the full release or preexisting selling pressure unrelated to the headline.
The headline states Apollomics regained full Nasdaq listing compliance, which is ordinarily a positive development for a company that had been at risk of delisting. However, the stock fell 25% on the day the compliance announcement was made. This disconnect suggests either the market knew compliance was coming and had already priced it in during an earlier recovery, or the full press release contained unfavorable details not captured in the headline snippet provided—such as dilutive equity issuance, clinical trial setbacks, management changes, or guidance reductions. Alternatively, the move may reflect unrelated market sentiment, short covering reversal, or a delayed reaction to other oncology sector headwinds. Without access to the complete press release text, the mechanism driving the sell-off remains unclear.
No news headlines were found in the last 48 hours, but KORU is a 3X leveraged ETF tracking South Korean equities, so a sharp 24.74% drop likely reflects a significant decline in the underlying MSCI South Korea index amplified by the fund's triple leverage.
The absence of any news in the last 48 hours suggests the move is not driven by company-specific announcements or ETF operational changes. However, KORU's structure as a daily reset 3X leveraged long ETF means its price movements are mechanically linked to the underlying MSCI South Korea index multiplied by three. A roughly 8.2% drop in the Korean market would produce approximately this magnitude of loss in KORU. This type of security is sensitive to broad market declines in South Korea, currency movements affecting Korean equities, regional geopolitical risk, or global risk-off sentiment. Without news or index data provided, the most probable explanation is that South Korean equities experienced a significant decline, with KORU's leverage amplifying that move. Intraday volatility or reset mechanics in leveraged ETFs can also produce outsized single-day moves.
No news headlines were published in the last 48 hours, so the 24.51% drop cannot be attributed to any identified company announcement or market event; the cause remains unknown without additional information.
The absence of recent news makes it impossible to pinpoint a specific catalyst for GMM's sharp 24.51% decline. For a speculative or lower-liquidity metaverse-focused equity like Global Mofy Metaverse Limited, significant single-day moves can occur for several reasons: broad sector rotation away from metaverse or virtual reality plays, general market weakness on July 13, 2026, technical breakdown or short-covering reversal, untracked social media or forum-driven sentiment shifts, institutional position unwinding, or delayed disclosure of adverse news not yet picked up by major financial feeds. Without corroborating headlines or structural data about the stock (float, short interest, recent offering activity), it is not possible to distinguish between these possibilities.
No news headlines were available in the last 48 hours for SDOT, so the 23% decline cannot be directly attributed to a specific announced event. The move likely reflects either delayed market reaction to unreported news, a technical sell-off, or sector-wide pressure.
The absence of any recent news in the Yahoo Finance RSS feed makes it impossible to pinpoint a specific catalyst for the 23.22% single-day decline. Sadot Group is a smaller-cap NASDAQ stock, which can be subject to heightened volatility and may experience sharp moves on limited volume. Possible categories of causes include an earnings miss or guidance reduction that was announced outside the tracked news window, a product or regulatory setback, insider selling or secondary offering activity, technical breakdown through support levels, or contagion selling related to sector or market-wide moves. Without additional information, these remain speculative hypotheses rather than confirmed causes.
DFNS fell 21.83% despite announcing a $1.1 million contract win from Rimon's Israeli defense customer on July 13, suggesting the market either viewed the deal as insufficient or a separate negative catalyst overshadowed the news.
The headline released on July 13 describes a concrete $1.1 million order delivery from T3 Defense's Rimon subsidiary to an Israeli defense customer for battlefield lighting systems. This is typically positive news and would ordinarily support a stock price. However, the stock posted a steep 21.83% decline on the same day it was announced, ranking in the top 19 biggest losers. This disconnect suggests either the market had already priced in expectations of a larger deal, the contract was perceived as inadequate relative to the company's valuation or burn rate, or a separate negative catalyst emerged that overshadowed the win. Alternatively, the announcement may have been preceded by an unmentioned earnings miss, guidance cut, or insider selling that triggered the decline, with the contract news arriving too late to recover the losses.
Aardvark Therapeutics fell 21.58% on July 13, 2026, with no news headlines in the prior 48 hours to explain the sharp decline, suggesting either a delayed market reaction to unannounced developments or a significant negative catalyst not yet captured in public sources.
No headlines from the past 48 hours are available to establish a specific cause for the 21.58% drop in AARD stock. A decline of this magnitude for a small-cap biotech typically correlates with material clinical trial setbacks, regulatory rejection or warning letters, failed financing announcements, insider selling disclosures, or significant equity dilution news. Alternatively, if Aardvark is a development-stage therapeutic company, sharp single-day moves can reflect updated market expectations about pipeline probability of success, loss of a key partnership, or negative feedback from investor conferences. Without contemporaneous headlines, the precise trigger remains unknown, though the magnitude and rank as a top-20 loser suggest an event material enough to move the entire market's assessment of the company's value or risk profile.
ClearOne fell 21.33% on July 13, 2026, but no news headlines are available from the last 48 hours to explain the sharp decline, making the specific catalyst unclear.
The absence of any recent news headlines in the Yahoo Finance RSS feed within 48 hours of the snapshot date makes it impossible to identify a confirmed catalyst for the 21.33% drop. ClearOne is a communications equipment and software company, and stocks in this sector typically respond to earnings misses, revenue guidance cuts, loss of major contracts, competitive pressures, or broader market selloffs in technology. Given the magnitude of the move and its ranking as the 21st biggest loser of the day, this appears to be company-specific rather than a broad market event. Possible explanations include an unannexed earnings announcement, product recall or technical issue, analyst downgrade, insider selling news, or a delayed press release not yet indexed in the RSS feed at snapshot time. Without headline confirmation, the true driver remains unknown.
PSQ Holdings fell 21.24% on July 13, 2026, with no relevant news headlines in the last 48 hours, making the direct catalyst unclear and likely driven by market technicals, sector rotation, or delayed earnings or corporate announcement.
No headlines were found in the last 48 hours that would explain the sharp 21.24% decline, which ranks PSQH as the 22nd biggest loser of the day. The lack of disclosed news makes attribution difficult. The magnitude of the move suggests either a significant corporate event not yet reflected in the news feeds queried, a broad sector selloff affecting holdings or competitors disproportionately, technical selling pressure from a support breakdown, or a delayed announcement from earlier that is only now being priced in. For a smaller cap NYSE-listed company like PSQ Holdings, illiquidity or institutional redemption could also amplify moves. Without access to real-time market commentary, SEC filings, or company guidance released outside standard news channels, the precise trigger remains unknown.
No news headlines were found in the last 48 hours for CPOP, so the 20.45% drop cannot be directly attributed to a named catalyst. The decline likely reflects technical selling, delayed news, or broader market sentiment toward the stock.
The absence of recent news makes it difficult to pinpoint a specific cause for CPOP's sharp 20.45% decline on July 13, 2026. Pop Culture Group is a micro-cap stock trading near $0.46, and stocks in this category often experience large percentage moves on relatively modest volume or investor repositioning, even without headline catalysts. Possible drivers include technical breakdown below support levels, liquidation pressure, delayed earnings or SEC filing releases not yet captured in the 48-hour news window, loss of investor interest in a particular sector or trading theme, or accumulation of negative sentiment from prior weeks that finally materialized in selling. Without access to intraday volume data, options activity, or insider transactions, distinguishing between these hypotheses is not possible.
Circle8 announced two $20 million Dutch public sector contract extensions on the same day it fell 20%, suggesting the market either viewed the news as insufficient, priced in bad news separately, or the sell-off was driven by unrelated factors such as broader sector weakness or technical selling.
The headline reports a positive commercial development: two contract extensions totaling $40 million from Dutch public sector clients, framed as demonstrating positive momentum. Ordinarily such an announcement would support the stock price or prove neutral. However, the stock declined sharply on the same day, which suggests either the market's reaction to the contract news was negative (perhaps due to underwhelming margins, delayed revenue recognition, or execution risk), or a separate negative catalyst emerged that overshadowed the announcement. Without additional headlines discussing earnings misses, guidance cuts, leadership changes, or sector-wide headwinds, the disconnect between the positive contract announcement and the sharp decline is unexplained. The stock's position as the 24th biggest loser also hints at possible broader selling pressure unrelated to Circle8-specific news.
No news headlines appeared in the last 48 hours to explain the 19.65% drop in STRS stock. The decline likely stems from an unannounced earnings release, guidance cut, or market-moving development not yet captured in available financial feeds.
Stratus Properties Inc. dropped nearly 20% with zero recent news coverage in the provided headlines, which is an unusual disconnect for such a large single-day move. For a real estate development company like Stratus, the most common catalysts for sharp declines are typically earnings misses or revised guidance on project timelines and profitability, unfavorable land-use or zoning decisions, changes in financing terms, or broader sector headwinds affecting residential or commercial real estate valuations. Without access to news from the past 48 hours beyond the Yahoo Finance RSS feed provided, it is possible that earnings were released, guidance was reduced, or a material announcement was made through other channels or company filings. The absence of headlines could also indicate a delayed indexing lag in the news feed rather than an absence of actual news.
No news headlines were found in the last 48 hours, so the 19.27% drop cannot be traced to a specific announced event. For a micro-cap stock like AMZE, the decline likely stems from technical selling, reduced liquidity, or undisclosed company developments.
The absence of any news in the last 48 hours makes it impossible to pinpoint a concrete catalyst for today's sharp decline. AMZE trades on AMEX at $0.09, suggesting it is a micro-cap or penny stock where price moves can be volatile and driven by factors other than headline events. Typical catalysts for stocks in this category include thin trading volume amplifying minor price movements, short-term speculative unwinding, delayed earnings or financial disclosures, regulatory filing issues, or broader sector weakness not yet reflected in news feeds. Without access to intraday social media discussion, market rumors, or company filing updates, the specific trigger remains unknown. The lack of recent news actually raises the possibility that the move was driven by technical factors or internal company matters not yet covered by major financial news outlets.
No headlines were found in the past 48 hours to explain the 19.22% drop in BYAH on July 13, 2026. Without recent news, the cause remains unknown, though biotech microcaps are prone to liquidity-driven moves and regulatory or clinical setbacks.
Yahoo Finance returned zero news items in the 48 hours preceding this sharp decline, making it impossible to tie the move to any specific announced catalyst such as clinical trial results, regulatory action, earnings, or management changes. Park Ha Biological Technology is a small-cap biotech listed on NASDAQ, a sector and market-cap combination historically susceptible to sudden moves on low trading volumes, delayed news dissemination, or company-specific announcements that may not yet have propagated through major news feeds. The 19.22% single-day loss could reflect a private placement, insider selling, a failed partnership negotiation, preclinical setback, or simply a technical unwind in a thinly traded name, but none of these can be confirmed from the available record. Biotech microcaps often experience outsized daily moves on minimal news or shifts in sentiment that take time to surface in public reporting.
No news headlines were found in the last 48 hours, but CIFG is a 2X leveraged ETF tracking CIFR, so a ~9-10% drop in the underlying likely caused the amplified ~19% loss seen here today.
CIFG is a daily rebalancing leveraged ETF with 2X exposure to CIFR. When the underlying index or security declines, this ETF's losses are magnified roughly twofold due to its leverage structure. Although no news headlines are available from the past 48 hours to point to a specific catalyst, the ~19% intraday loss is consistent with approximately a 9-10% decline in CIFR itself. The lack of news does not rule out intraday volatility driven by technical selling, sector rotation, or market-wide risk-off moves. Without information on CIFR's actual daily performance or any company-specific news, we cannot pinpoint whether the decline stems from CIFR earnings, guidance, a sector selloff, or other structural factors. The loss magnitude is explained by leverage, but the root cause remains unknown.
Nuburu announced a premium-priced public offering to fund an acquisition and pay down debt, which typically dilutes existing shareholders and triggered an 18.77% drop as investors reacted to the equity offering announcement.
On July 13, 2026, Nuburu announced a proposed best-efforts public offering designed to raise capital for two stated purposes: to consummate the acquisition of a controlling interest in Tekne and to extinguish outstanding indebtedness and related stock-based amortizations. The description "premium-priced" suggests the offering price may be above or at market, but the announcement of new equity issuance—especially one described as "best-efforts" rather than firm commitment—typically signals dilution risk to existing shareholders. The stock's 18.77% single-day decline is consistent with equity dilution concerns, though the full offering size and pricing were not disclosed in the headline excerpt. The timing of the announcement and immediate sharp decline suggests the market had not previously priced in this capital raise event.
No news headlines were found in the last 48 hours, but IONX is a 2X leveraged ETF tracking IONQ, so a roughly 9% drop in the underlying quantum computing stock would mechanically produce an 18% decline in this leveraged product.
The absence of any news in the provided headlines does not explain the move directly, but IONX's structure offers a clear mechanical explanation. IONX is designed to deliver twice the daily return of the underlying IONQ stock. A -9% move in IONQ would translate to approximately -18% in IONX, which matches the observed decline. This means the loss is likely driven by weakness in the quantum computing sector or IONQ specifically rather than any fund-level event. Without headlines about IONQ itself, we cannot pinpoint whether the move reflects earnings disappointment, sector rotation, profit-taking after prior gains, or broader market sentiment toward speculative tech. The leveraged nature of IONX amplifies both upside and downside volatility compared to holding IONQ directly.
No news headlines available in the last 48 hours, but IONL is a 2x leveraged ETF tracking IONQ stock, so an 18.63% drop likely reflects a roughly 9% decline in the underlying IONQ shares driven by an unreported market development.
IONL is a daily reset leveraged ETF that aims to deliver twice the daily return of the IONQ quantum computing stock. With no news headlines provided for the last 48 hours, we cannot identify a specific catalyst. However, the magnitude of the decline is consistent with leveraged ETF behavior during downturns in the underlying security. The most likely categories of cause are either unreported negative developments in IONQ itself (technical breakdown, sector rotation out of quantum computing, or a delayed market reaction to prior news), deterioration in the broader technology or speculative equity space, or a gap down opening that occurred before news would have appeared in the RSS feed. Without documentation of IONQ's own price action or any news related to IONQ operations or sentiment, attribution remains speculative.
No news headlines were published in the last 48 hours, so the 18% decline in ONFO cannot be attributed to a disclosed event; the drop likely stems from technical selling, untracked news flow, or broader market pressure on microcap stocks.
The absence of any headlines in the Yahoo Finance RSS feed over the past two days means there is no identifiable news catalyst on record for this move. ONFO is a microcap security trading at $0.16, a price point typical of distressed, speculative, or post-restructuring companies. Stocks in this category are sensitive to several generic drivers: technical breakdown below support levels, redemptions or forced selling by fund managers, short-squeeze reversals, or delayed regulatory filings and announcements that may not immediately propagate to major news feeds. Without access to press releases, SEC filings, insider trades, or real-time message boards, it is impossible to pinpoint whether the decline was triggered by company-specific fundamentals, a short squeeze unwind, or purely mechanical selling pressure. The rank as the 32nd biggest loser suggests meaningful volume participation, but rank alone does not reveal causation.
Fort Technology Inc. fell 17.74% on July 13, 2026, with no news headlines in the last 48 hours, suggesting the decline was driven by technical selling, market-wide weakness, or undisclosed news not yet captured in major financial media.
The absence of any identified news headlines in the 48 hours preceding this sharp 17.74% drop makes it impossible to pinpoint a specific catalyst. For a microcap or thinly traded stock like FRTT trading near $1.02, declines of this magnitude can result from several common drivers: a missed or delayed earnings announcement, insider selling or insider lock-up expiration, a negative analyst downgrade not yet syndicated widely, broader sector rotation out of technology stocks, or technical selling pressure on a stock approaching or breaching a key support level. Another possibility is that material news was released outside the Yahoo Finance RSS feed window or through a different distribution channel. Without contemporaneous headlines or company filings visible in the data provided, attributing the move to any specific event would be speculative. The rank as the 33rd biggest loser suggests broad market participation in the decline rather than isolation to a single story.
VTAK fell 17.67% with no news reported in the last 48 hours, making the cause impossible to determine from available information. The drop may reflect broader market sentiment, technical selling, or an unreported development.
No headlines were available in the last 48 hours to explain Catheter Precision's sharp decline. For a micro-cap medical device company trading at $0.65, price movements are typically driven by clinical trial results, FDA regulatory actions, partnership announcements, or cash position updates. Absent any reported catalyst, the move could reflect technical breakdown in a thinly traded security, sector-wide weakness in interventional devices, delayed disclosure of adverse events or trial data, or opportunistic short selling. Without access to company filings, SEC notifications, or social media chatter from the snapshot date itself, attribution remains speculative.
YY Group (YYGH) fell 17.48% on July 13, 2026, with no identifiable news headlines in the last 48 hours to explain the sharp decline, suggesting either a delayed market reaction, technical selling, or undisclosed corporate event.
No news headlines were found in the last 48 hours that would directly account for YYGH's 17.48% single-day drop. This leaves several plausible avenues. First, the decline could reflect a delayed market reaction to news released earlier than the 48-hour window or an announcement outside mainstream financial feeds. Second, YYGH is a Chinese-listed company trading on NASDAQ, making it vulnerable to sector-wide pressure on Chinese tech stocks, regulatory concerns, or currency headwinds that may not always generate discrete headlines. Third, the stock could have experienced technical selling triggered by a broken support level, options expiration mechanics, or institutional rebalancing. Fourth, undisclosed insider transactions, earnings preannouncements, or corporate guidance cuts can sometimes move stocks without immediate public disclosure. Without headline evidence, the most likely driver is sector pressure on Chinese equities or a technical breakdown in the stock itself rather than company-specific news.
No news headlines were found in the last 48 hours explaining AMPGZ's 16.81% decline on July 13, 2026. The drop likely stems from either broader market sentiment, technical selling, or undisclosed company developments not yet published by Yahoo Finance.
The absence of recent news headlines makes it impossible to identify a specific catalyst for today's sharp 16.81% decline in AMPGZ. This security is a Series B right offering from Amplitech Group, a specialized RF and microwave component manufacturer serving defense and aerospace markets. Rights offerings typically trade based on the intrinsic value derived from their underlying redemption terms and the parent company's stock performance. Without headline evidence, the decline could reflect several plausible scenarios: weakness in parent company AMPG itself due to defense spending concerns or operational headwinds, technical profit-taking after a prior rally, broader market volatility affecting small-cap securities, or announcement-driven moves that have not yet been captured in the RSS feed lag. The rank as the 36th biggest loser suggests moderate but not exceptional selling pressure across the market that day.
No financial news was published in the last 48 hours to explain the 16.27% drop, so the catalyst remains unclear and could stem from technical selling, unreported company-specific developments, or broader market conditions.
The absence of any headlines in the last 48 hours makes it impossible to anchor the move to a specific corporate event or market-moving announcement. DAIC experienced a sharp single-day decline ranking it among the day's 37 biggest losers, but without supporting news the underlying cause is speculative. For a small-cap or micro-cap stock like this, typical catalysts for unexplained sharp drops include delayed or post-market regulatory filings, insider transactions, sector rotation, technical breakdown of support levels, options expiration effects, or adverse rumors circulating in private channels that have not yet reached mainstream financial media. The stock's low absolute price of $1.39 also suggests it may be more volatile and subject to retail-driven technical moves than fundamental catalysts.
Cadrenal announced positive Phase 2 data for CAD-1005 showing greater than 25% reduction in thrombotic events in HIT at ISTH 2026 Congress, yet the stock fell 16.26%, suggesting investors may have had higher expectations or the market focused on unmentioned trial limitations.
The headline describes late-breaking Phase 2 data presented at a major thrombosis conference, highlighting a greater than 25% reduction in thrombotic events for the company's first-in-class 12-LOX inhibitor CAD-1005 in HIT (heparin-induced thrombocytopenia). This appears to be positive clinical news selected as one of three late-breakthrough abstracts at the largest ISTH meeting in over a decade. However, the stock dropped sharply on the same day, which is counterintuitive for a clinical readout that seems positive on its face. Possible explanations include that the market had priced in more substantial efficacy gains, investors noted safety concerns or secondary endpoints that were not emphasized in the headline, or the stock experienced profit-taking after a prior run-up. Without access to the full abstract details or the stock's recent price history, it is difficult to pinpoint whether the disappointment was relative (good but not great) or driven by factors outside the headline.
No news headlines were found in the last 48 hours, so the 16% decline cannot be attributed to any announced company development or market event in the available record. The drop likely reflects technical selling, sector rotation, or undisclosed news.
PDC (Perpetuals.com Ltd) fell 16.19% to rank among the day's 39 biggest losers, yet no news headlines appear in the last 48 hours to explain the move. This disconnect suggests either the catalyst occurred before the news cycle captured it, exists in channels not tracked by the RSS feed provided, or reflects technical pressure unrelated to fundamental announcements. For a small-cap equity like this, typical drivers of sharp single-day declines include margin calls or forced liquidations in leveraged positions, short-seller reports or social-media campaigns, missed earnings or guidance surprises reported outside mainstream wires, sector-wide selloffs, or algorithmic unwinds. Without access to company filings, insider trading alerts, or social sentiment data, the specific trigger remains unknown.
No news headlines were found in the last 48 hours to explain the 15.98% drop in YMAT, so the cause remains unclear from available information.
J-Star Holding Co., Ltd. (YMAT) fell 15.98% on July 13, 2026, but no news headlines were published in the preceding 48 hours on Yahoo Finance RSS to account for this decline. The absence of disclosed catalysts leaves the driver of the move in the unknown category. For a stock trading at $2.05 on a smaller exchange listing, typical causes of sharp single-day declines without concurrent news include sector rotation, technical breakdown of support levels, delayed reporting of after-hours announcements, insider transactions, or broader market liquidity events. Without access to real-time order flow, social media discussion, or earnings calendar information, any attribution would be speculative. The rank as the 40th biggest loser suggests sector-wide pressure is unlikely; the move appears more idiosyncratic to YMAT itself.
No news headlines were available in the last 48 hours, but MRVU is a 2X leveraged bull ETF tracking Marvell Semiconductor, so a sharp drop likely reflects a significant decline in MRVL stock itself, which would be amplified approximately twofold in this fund.
The absence of news in the Yahoo Finance RSS feed for the past 48 hours means we cannot identify a specific catalyst from headlines. However, MRVU's structure as a Direxion Daily Bull 2X ETF is directly relevant to understanding this move. This is a leveraged instrument designed to deliver twice the daily return of its underlying asset, Marvell Semiconductor (MRVL). A 15.97% single-day drop in MRVU would imply roughly an 8% decline in MRVL itself. Such a semiconductor stock decline could stem from sector rotation, broader market weakness, company-specific negative news, or technical factors in chip stocks. Without access to MRVL-specific news or market data for July 13, 2026, we cannot pinpoint whether this reflects company earnings disappointment, guidance cuts, competitive pressures, or general market sell-off dynamics affecting semiconductor cyclicals.
No news headlines were available in the last 48 hours, so the 15.93% drop cannot be attributed to a specific disclosed event; the decline likely reflects technical selling, sector rotation, or undisclosed market sentiment.
N2OFF experienced a sharp 15.93% single-day decline ranking it among the day's biggest losers, yet no news headlines appeared in the most recent 48-hour period on Yahoo Finance. This disconnect between a material move and absence of disclosed catalysts is common for lower-volume or micro-cap stocks where price action can be driven by technical factors, options expiration, short covering or accumulation, sector-wide pressure, or rumors not yet reflected in major financial wire services. Without access to earnings calendars, insider trading activity, or real-time social sentiment, the specific trigger remains opaque. The stock's price level and apparent liquidity profile suggest it may be more sensitive to technical and sentiment-driven moves than larger-cap securities.
Cue Biopharma fell 15.93% despite announcing a new Chief Medical Officer on July 13, suggesting the market reacted negatively to either internal leadership shifts, unmet clinical expectations, or broader sector headwinds unrelated to the CMO appointment itself.
The provided headlines show two pieces of information: a general market report on head and neck squamous cell carcinoma immunotherapy growth, and Cue's appointment of Dominic Borie as CMO and head of R&D. The CMO announcement is nominally positive, as it signals leadership depth in clinical and research functions. However, the 15.93% single-day drop contradicts any bullish interpretation of the news provided. This suggests either the market has negative information not captured in these headlines, the appointment announcement masked disappointing clinical trial data or pipeline updates released simultaneously, or the sell-off reflects sector-wide pressure in biotech immunotherapy stocks unrelated to Cue specifically. Without access to the full press release, earnings call, or contemporaneous sell-side research, the true catalyst remains unclear.
No news headlines were found in the last 48 hours to explain ZSQR's 15.89% drop, so the cause remains unclear; it could involve earnings, clinical setbacks, insider moves, or market technicals for this small-cap biotech name.
Yahoo Finance returned no headlines for Coeptis Therapeutics in the 48 hours prior to this 15.89% decline on July 13, 2026. For a small-cap biotech trading at $7.20, the absence of public news does not rule out a material catalyst. Biotech stocks commonly react sharply to clinical trial results, regulatory feedback, financing announcements, or leadership changes, which may not immediately surface in broad RSS feeds. Alternatively, the move could reflect technical liquidation, short covering reversal, insider selling, or delayed market reaction to an announcement not yet indexed by the data source. Without headline confirmation, we cannot distinguish between clinical disappointment, capital structure stress, or trading mechanics.
No news headlines were found in the last 48 hours, so the 15.86% drop likely reflects a delayed market reaction to an earlier announcement, a technical sell-off, or untracked negative catalyst in the micro-cap diagnostics space.
Bluejay Diagnostics is a small-cap diagnostic company trading near $1.22, and today's 15.86% decline ranks it among the day's biggest losers. However, no news headlines appear in the available feed from the past 48 hours. This absence of tracked news does not rule out a material catalyst. Common causes for this type of move in micro-cap diagnostic firms include clinical trial setbacks, regulatory delays, funding or liquidity concerns, guidance reductions, or loss of a key partnership or contract. The stock's low price and micro-cap status make it sensitive to both company-specific developments and broad sector sentiment shifts. Without identified headlines, we cannot definitively link today's move to a specific event, though delayed market digestion of earlier announcements or untracked press releases remain plausible.
Universe Pharmaceuticals dropped 15.56% with no news headlines in the last 48 hours, suggesting the move was driven by technical selling, sector rotation, or undisclosed corporate developments not yet captured in major financial media.
The absence of any news in the Yahoo Finance RSS feed over the last two days makes it difficult to identify a specific catalyst for UPC's sharp decline. For a small-cap pharmaceutical company, typical drivers of such moves include clinical trial results (negative or delayed), regulatory setbacks, insider selling, shifts in analyst sentiment, or broader sector headwinds affecting biotech valuations. It is also possible the stock experienced technical breakdown after hitting resistance, liquidation pressure from a fund, or negative commentary on social media or specialty channels that had not yet propagated to mainstream headlines. Without corroborating news, we cannot definitively attribute the move to any single event, though pharmaceutical stocks are particularly sensitive to binary clinical and regulatory events that sometimes move prices before formal press releases reach major financial wire services.
No news headlines were found in the last 48 hours for NWGL, so the 15.31% drop cannot be directly attributed to a published company announcement or market-moving event. The decline likely reflects technical selling, liquidity constraints typical of micro-cap stocks, or untracked news.
The absence of any recent news headlines makes it difficult to pinpoint a specific catalyst for today's decline. NWGL trades at $0.25, a penny-stock price point that typically indicates either a severely distressed company, a shell entity, or a stock trading at reduced valuations. Stocks in this category are frequently subject to sharp moves driven by technical factors such as stop-loss cascades, thinly-traded conditions that amplify small trades into large percentage swings, or off-exchange discussions and rumors not immediately captured in major news feeds. Alternatively, the decline could reflect delayed disclosure of material news, insider selling, or regulatory filing issues that have not yet propagated to mainstream financial news sources. Without headline confirmation, any specific attribution remains speculative.
No news headlines were found in the last 48 hours, but MVLL is a 2x leveraged ETF tracking Marvell Semiconductor, so a sharp intraday drop likely reflects a similarly sharp decline in MRVL stock itself, amplified by the leverage structure.
The absence of any news in the provided headlines makes direct causation impossible to establish from public announcements. However, MVLL's structure as a 2x daily leveraged long ETF on Marvell Semiconductor means it will amplify both gains and losses of the underlying stock by approximately two times on a daily basis. A 15.28% drop in MVLL would be consistent with roughly a 7-8% decline in MRVL shares themselves. The likely catalyst would therefore be a move in Marvell's own stock price, which could stem from sector-wide semiconductor weakness, company-specific news that has not yet appeared in this RSS feed, broader market conditions, or technical selling. Without headlines confirming a specific event, the mechanism is clear but the root cause remains unknown.
Rackspace reported a revised downward revenue outlook for FY26 in its Q2 earnings call, offsetting positive messaging about an AI-focused strategic pivot, triggering a 15% sell-off as investors reacted to reduced guidance.
The headline explicitly references a "revised revenue outlook for FY26" alongside Rackspace's strategic shift toward AI and higher-margin business. In equity markets, downward guidance revisions typically drive sharp single-day losses, especially when they surprise the Street or reflect operational headwinds that contradict near-term growth expectations. The concurrent messaging about AI pivot and margin expansion is positive in principle, but appears to have been overshadowed by the FY26 revenue reduction. The scale of the decline (15.28%) suggests the guidance cut was material enough to reset investor expectations. Without the full earnings release, we cannot quantify the magnitude of the revision or determine whether the market had priced in different assumptions, but the timing and size of the move align cleanly with a guidance disappointment on the earnings call.
No news headlines were found in the last 48 hours, but ARMG is a 2x leveraged long ETF on ARM Holdings, so a sharp decline likely reflects a significant drop in the underlying ARM stock or broader semiconductor sector weakness.
The absence of headlines specific to ARMG or ARM Holdings in the last 48 hours means we cannot point to a named catalyst such as earnings, product announcements, or analyst downgrades. However, ARMG's structure as a daily 2x leveraged long ETF is the key explanatory insight here. This fund amplifies daily moves in its underlying ARM Holdings stock by a factor of two. A 15.27% drop in ARMG would correspond to roughly a 7.6% decline in ARM itself. Such a move would typically stem from sector-wide semiconductor weakness, broader market selloff, or ARM-specific negative developments that either occurred before the 48-hour window or were not yet captured in the provided news feed. Without access to ARM's actual intraday performance or market-wide conditions on July 13, 2026, we cannot definitively rule out technical selling, options expiration effects, or other mechanical factors specific to leveraged ETFs.